Asher Schachter, MD, MMSc, MS

Division of Nephrology, Children's Hospital Boston
Children's Hospital Informatics Program at Harvard-MIT Health Sciences & Technology
Assistant Professor of Pediatrics, Harvard Medical School

research	Predictive modeling in pediatric drug development Summary Dr. Schachter is focused on optimizing predictive models in drug development, with the primary objective of reducing the prevalence of unsafe drugs, reducing post-approval adverse events, and improving the stature of children in the drug development domain. His novel approach to model populations of drugs rather than populations of patients has also proven of value in advocating for industry-wide data sharing and for renewal and improvement in pediatric drug development legislation. Dr. Schachter's most recent innovative approach is aimed at predicting serious adverse events caused by FDA-approved drugs, using models that are based solely on preclinical data. This new approach requires no first-in-human drug trial data to predict rare but serious post-approval adverse events that affect millions of lives annually.
positions, honors & funding	1999-present: Attending Nephrologist, Children's Hospital Boston 1999-2004: Instructor in Pediatrics, Harvard Medical School 2000-2005: NIH K23 Career Development Award 2003-present: CHIP Faculty 2003-04: Sloan Industry Center Fellowship, MIT: Predictive Modeling in Drug Development 2004-present: Assistant Professor of Pediatrics, Harvard Medical School 2005-present: SPR, nominated member 2006-present: Visiting Investigator, Drummond Lab, MGH East 2006-07: Ad Hoc Reviewer, PBKD Study Section, NIDDK, NIH 2006-07: NKF MA/RI/NH/VT Pediatric Renal Research Award 2007-09: Children's Hospital Boston Faculty Development Award: Predictive Modeling for Pediatric Drug Development 2008-09: Co-PI, R43 (NCI), Decision support software for cancer drug development 2008-12: PI, R01 (NIGMS), Preclinical predictive markers of post-approval drug safety
training	Academic 1992: MD, University of Toronto, Canada 2001: MMSc, Harvard-MIT HST Clinical Investigator Training Program 2003: MS, Harvard-MIT HST Biomedical Informatics Clinical 1992-1996: Pediatric Residency, The Hospital For Sick Children, Toronto 1996-1999: Nephrology Fellowship, Children's Hospital Boston Certification 1995: Certification in Pediatrics, American Board of Pediatrics 1996: FRCP (Canada) Specialist Certificate in Pediatrics 1999: Certification in Pediatric Nephrology, American Board of Pediatrics 2002: Re-certification in Pediatrics, American Board of Pediatrics 2006: Re-certification in Pediatric Nephrology, American Board of Pediatrics
publications in press	Drug Development citation list on PubMed Complete citation list on PubMed Schachter AD, and Ramoni MF. Paediatric Drug Development. Nature Reviews Drug Discovery, Nature Reviews Drug Discovery, June 2007, 6(6):429-430 Schachter AD, Ramoni MF, Baio G, Roberts TG, and Finkelstein SF. Economic evaluation of a Bayesian model to predict late phase success of new chemical entities. *Value Health, advanced online publication, June 15, 2007.* Schachter AD, and Ramoni MF. Clinical Forecasting in Drug Development. Nature Reviews Drug Discovery, Feb. 2007, 6(2):107-108.